Pharmasyntez, one of the leaders of Russian pharmaceutical industry in the segment of antituberculosis, ARV and oncological medications, enters the market with a new portfolio of hypoglycemic drugs.
The production facility is located in the city of Tyumen, where a new plant was built on the basis of existing capacities. The new plant meets the highest and most advanced GMP requirements and standards. The investments in this project amounted to more than 3 billion rubles. The construction was supported by the Russian Ministry of Industry and Trade, the Government of the Tyumen Region and personally by the Governor Vladimir Yakushev.
In Q4 2017, LLC Pharmasyntez-Retail, a member of Pharmasyntez Group will bring to the Russian market a wide range of traditional hypoglycemic drugs, such as gliclazide, repaglinide, metformin, glibenclamide, glimepiride, gliquidone, glibenclamide + metformin. This will allow to fully meet the demands of Russian consumers for high-quality and affordable medicines of this nosology.